{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:01:13Z","timestamp":1787032873513,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,9]]},"DOI":"10.7759\/cureus.98858","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T06:38:53Z","timestamp":1765348733000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Tirzepatide and Semaglutide for Obesity Management: A Real-World Comparison"],"prefix":"10.7759","author":[{"given":"Kishore Kumar","family":"Shil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananda D","family":"Hira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudipta","family":"Bakchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanta K","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmud","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish K","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00397-6","article-title":"Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021","volume":"405","author":"Kerr JA","year":"2025","unstructured":"Kerr JA, Patton GC, Cini KI, et al.. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet. 2025, 405:785-812. 10.1016\/S0140-6736(25)00397-6","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-50973-w","article-title":"Trends estimation of obesity prevalence among South Asian young population: a systematic review and meta-analysis","volume":"14","author":"Bansal D","year":"2024","unstructured":"Bansal D, V S MS, Devi N, Boya C, Dhora Babu K, Dutta P. Trends estimation of obesity prevalence among South Asian young population: a systematic review and meta-analysis. Sci Rep. 2024, 14:596. 10.1038\/s41598-023-50973-w","journal-title":"Sci Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s40795-025-01018-0","article-title":"Investigating inequality of childhood obesity in Bangladesh: a decomposition analysis","volume":"11","author":"Sarker AR","year":"2025","unstructured":"Sarker AR. Investigating inequality of childhood obesity in Bangladesh: a decomposition analysis. BMC Nutr. 2025, 11:164. 10.1186\/s40795-025-01018-0","journal-title":"BMC Nutr"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2337\/dsi24-0002","article-title":"Using second-generation anti-obesity medications","volume":"37","author":"Schmitz SH","year":"2024","unstructured":"Schmitz SH, Aronne LJ. Using second-generation anti-obesity medications. Diabetes Spectr. 2024, 37:303-12. 10.2337\/dsi24-0002","journal-title":"Diabetes Spectr"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59558","article-title":"A real-world study of the effectiveness and safety of semaglutide for weight loss","volume":"16","author":"Tzoulis P","year":"2024","unstructured":"Tzoulis P, Batavanis M, Baldeweg S. A real-world study of the effectiveness and safety of semaglutide for weight loss. Cureus. 2024, 16:e59558. 10.7759\/cureus.59558","journal-title":"Cureus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7570\/jomes22067","article-title":"Efficacy and safety of tirzepatide in type 2 diabetes and obesity management","volume":"32","author":"Sinha R","year":"2023","unstructured":"Sinha R, Papamargaritis D, Sargeant JA, Davies MJ. Efficacy and safety of tirzepatide in type 2 diabetes and obesity management. J Obes Metab Syndr. 2023, 32:25-45. 10.7570\/jomes22067","journal-title":"J Obes Metab Syndr"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-023-01321-5","article-title":"Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis","volume":"47","author":"Tan B","year":"2023","unstructured":"Tan B, Pan XH, Chew HS, et al.. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. Int J Obes. 2023, 47:677-85. 10.1038\/s41366-023-01321-5","journal-title":"Int J Obes"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S392684","article-title":"Novel anti-obesity therapies and their different effects and safety profiles: a critical overview","volume":"16","author":"Telci Caklili O","year":"2023","unstructured":"Telci Caklili O, Cesur M, Mikhailidis DP, Rizzo M. Novel anti-obesity therapies and their different effects and safety profiles: a critical overview. Diabetes Metab Syndr Obes. 2023, 16:1767-74. 10.2147\/DMSO.S392684","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf084","article-title":"Global rise of compounded weight-loss medicines: a worrisome trend","volume":"9","author":"Sood N","year":"2025","unstructured":"Sood N, Garg R. Global rise of compounded weight-loss medicines: a worrisome trend. J Endocr Soc. 2025, 9:bvaf084. 10.1210\/jendso\/bvaf084","journal-title":"J Endocr Soc"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13543","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials","volume":"24","author":"Alkhezi OS","year":"2023","unstructured":"Alkhezi OS, Alahmed AA, Alfayez OM, Alzuman OA, Almutairi AR, Almohammed OA. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials. Obes Rev. 2023, 24:e13543. 10.1111\/obr.13543","journal-title":"Obes Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7570\/jomes23032","article-title":"Approved anti-obesity medications in 2022 KSSO guidelines and the promise of phase 3 clinical trials: anti-obesity drugs in the sky and on the horizon","volume":"32","author":"Jeon E","year":"2023","unstructured":"Jeon E, Lee KY, Kim KK. Approved anti-obesity medications in 2022 KSSO guidelines and the promise of phase 3 clinical trials: anti-obesity drugs in the sky and on the horizon. J Obes Metab Syndr. 2023, 32:106-20. 10.7570\/jomes23032","journal-title":"J Obes Metab Syndr"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-061324-011832","article-title":"Weight loss blockbuster development: a role for unimolecular polypharmacology","volume":"65","author":"Zhou Q","year":"2025","unstructured":"Zhou Q, Li G, Hang K, Li J, Yang D, Wang MW. Weight loss blockbuster development: a role for unimolecular polypharmacology. Annu Rev Pharmacol Toxicol. 2025, 65:191-213. 10.1146\/annurev-pharmtox-061324-011832","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001356","article-title":"2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"152","author":"Jones DW","year":"2025","unstructured":"Jones DW, Ferdinand KC, Taler SJ, et al.. 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025, 152:e114-218. 10.1161\/CIR.0000000000001356","journal-title":"Circulation"},{"key":"ref14","article-title":"The Asia-Pacific perspective: redefining obesity and its treatment","author":"World Health Organization","year":"2000","unstructured":"World Health Organization. The Asia-Pacific perspective: redefining obesity and its treatment. WHO, Sydney; 2000."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12889","article-title":"Management of overweight and obesity in primary care - a systematic overview of international evidence-based guidelines","volume":"20","author":"Semlitsch T","year":"2019","unstructured":"Semlitsch T, Stigler FL, Jeitler K, Horvath K, Siebenhofer A. Management of overweight and obesity in primary care - a systematic overview of international evidence-based guidelines. Obes Rev. 2019, 20:1218-30. 10.1111\/obr.12889","journal-title":"Obes Rev"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.86080","article-title":"Tirzepatide versus semaglutide for weight loss in overweight and obese adults: a systematic review and meta-analysis of direct comparative studies","volume":"17","author":"Munawar N","year":"2025","unstructured":"Munawar N, Mahato A, Rawat A, et al.. Tirzepatide versus semaglutide for weight loss in overweight and obese adults: a systematic review and meta-analysis of direct comparative studies. Cureus. 2025, 17:e86080. 10.7759\/cureus.86080","journal-title":"Cureus"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr6231","article-title":"Comparative efficacy of tirzepatide vs. semaglutide in reducing body weight in humans: a systematic review and meta-analysis of clinical trials and real-world data","volume":"17","author":"Aamir AB","year":"2025","unstructured":"Aamir AB, Latif R, Alqoofi JF, Almarzoq FA, Fallatah JO, Hassan GA, Saab FA. Comparative efficacy of tirzepatide vs. semaglutide in reducing body weight in humans: a systematic review and meta-analysis of clinical trials and real-world data. J Clin Med Res. 2025, 17:285-96. 10.14740\/jocmr6231","journal-title":"J Clin Med Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas JP","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021, 385:503-15. 10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06144-1","article-title":"Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials","volume":"67","author":"Karagiannis T","year":"2024","unstructured":"Karagiannis T, Malandris K, Avgerinos I, et al.. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia. 2024, 67:1206-22. 10.1007\/s00125-024-06144-1","journal-title":"Diabetologia"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez PJ","year":"2024","unstructured":"Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ, Stucky NL. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med. 2024, 184:1056-64. 10.1001\/jamainternmed.2024.2525","journal-title":"JAMA Intern Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15333","article-title":"Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials","volume":"26","author":"Patel H","year":"2024","unstructured":"Patel H, Khunti K, Rodbard HW, Bajaj HS, Bray R, Kindracki Z, Rodr\u00edguez \u00c1. Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diabetes Obes Metab. 2024, 26:473-81. 10.1111\/dom.15333","journal-title":"Diabetes Obes Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01765-z","article-title":"Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial","volume":"22","author":"Sandsdal RM","year":"2023","unstructured":"Sandsdal RM, Juhl CR, Jensen SB, et al.. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovasc Diabetol. 2023, 22:41. 10.1186\/s12933-023-01765-z","journal-title":"Cardiovasc Diabetol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/433827-efficacy-and-safety-of-tirzepatide-and-semaglutide-for-obesity-management-a-real-world-comparison","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T06:38:54Z","timestamp":1765348734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/433827-efficacy-and-safety-of-tirzepatide-and-semaglutide-for-obesity-management-a-real-world-comparison"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.98858","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,9]]}}}